The Food and Drug Administration (FDA) has granted approval to daraxonrasib, a new drug designed to treat advanced pancreatic cancer by targeting a mutated protein crucial for tumor growth. This marks a significant development in treating one of the deadliest forms of cancer, offering U.S. patients a more effective therapeutic option.
The daily pill, to be marketed as Rasonque by Revolution Medicines, addresses a mutated protein that fuels tumor growth in over 90% of pancreatic cancer cases, a challenge that had long eluded drug developers. Clinical studies indicated that patients receiving daraxonrasib experienced a near doubling of their survival time compared to those undergoing traditional chemotherapy.
In a study involving 500 patients whose metastatic cancer had ceased responding to previous treatments, those on the new drug lived a median of 13.2 months, contrasting with the 6.7 months for patients on chemotherapy. Common side effects reported included skin rash, mouth sores, and digestive issues.
Pancreatic cancer remains exceptionally lethal due to its propensity to spread before detection. The American Cancer Society estimates approximately 67,000 new cases will be diagnosed in the U.S. this year, with over 52,000 deaths. The overall five-year survival rate currently stands at 13%.
The newly approved drug targets mutations in the RAS gene family, particularly KRAS mutations, which are known drivers of pancreatic cancer. Historically, the protein's structure made it difficult to target, earning it the designation "undruggable." Daraxonrasib employs a molecular glue mechanism to bind to multiple KRAS subtypes.
Doctors involved in treating pancreatic cancer express optimism that this drug may pave the way for additional treatment avenues. Revolution Medicines is also investigating its technology for other cancer types, including lung cancer. The FDA's accelerated approval underscores its commitment to expediting access to meaningful treatments for patients.